Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Research output: Contribution to journalArticle

Abstract

Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile. Discussion: Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response. Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.

Original languageEnglish
Pages (from-to)29-33
Number of pages5
JournalOncology (Switzerland)
Volume94
DOIs
Publication statusPublished - Jul 1 2018

    Fingerprint

Keywords

  • Brain metastasis
  • Breast cancer
  • Eribulin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this